CATT of course tested ranibizumab (Lucentis) as the control against bevacizumab (Avastin) and not aflibercept (Eylea) against bevacizumab (Lucentis).
Apologies. I was too late to edit my above post.
CATT of course tested ranibizumab (Lucentis) as the control...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
56.0¢ |
Change
0.005(0.90%) |
Mkt cap ! $689.4M | |||
| Open | High | Low | Value | Volume |
| 55.0¢ | 56.5¢ | 55.0¢ | $1.173M | 2.097M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 30360 | 55.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 57.0¢ | 35361 | 3 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| OPT (ASX) Chart |